Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 3Phase 4 2Phase 1/2 2

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Lymphoma 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × axicabtagene ciloleucel × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT05794958 2025-09-23

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Stanford University

Phase 1 Recruiting
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Lymphoid

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡